1228430-85-0

Basic information

• Product Name: 6-Methyl-3-phenylpyridine-2-carboxylic acid
• Synonyms: 6-Methyl-3-phenylpyridine-2-carboxylic acid
• CAS NO: 1228430-85-0
• Molecular Formula: C₁₃H₁₁NO₂
• Molecular Weight: 213.23194
• Mol File: 1228430-85-0.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-Methyl-3-phenylpyridine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Methyl-3-phenylpyridine-2-carboxylic acid(1228430-85-0)
• EPA Substance Registry System: 6-Methyl-3-phenylpyridine-2-carboxylic acid(1228430-85-0)

Safety Data

• Hazardous Substances Data: 1228430-85-0(Hazardous Substances Data)

Upstream product

• 42097-42-7 3-hydroxy-2-hydroxymethyl-6-methylpyridine 
• 1445596-16-6 methyl 6-methyl-3-phenylpicolinate 
• 1228188-33-7 methyl-3-iodo-6-methylpyridine-2-carboxylate 
• 98-80-6 phenylboronic acid 
• 1233520-21-2 (6-methyl-3-phenyl-2-pyridinyl)methanol 
• 1228430-84-9 6-methyl-3-(tributylstannanyl)-2-{[(tributylstannanyl)oxy]carbonyl}pyridine 
• 603-35-0 triphenylphosphine 

Downstream Products

• 1233520-65-4 6-fluoro-8-methyl-2-({(2S)-1-[(6-methyl-3-phenyl-2-pyridinyl)carbonyl]-2-piperidinyl}methyl)imidazo[1,2-a]pyridine 
• 1252905-71-7 (1R,4S,6R)-4-({[(1,1-dimethylethyl)(diphenyl)silyl]oxy}methyl)-3-[(6-methyl-3-phenyl-2-pyridinyl)carbonyl]-3-azabicyclo[4.1.0]heptane 

Relevant articles and documents

NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES

This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar1 and Ar2 have meanings given in the description.

CHEMICAL COMPOUNDS

The invention relates to a novel compound of formula (I) or a stereoisomer, or a racemate or a mixture or a pharmaceutically acceptable salt thereof: wherein: R is phenyl or a 5- or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from S, N and O, such rings may be optionally substituted with n groups Q; Q is selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, SO2CH3 or a group —O[(CR1R2]pQ1; or Q may be a group Q2; Q1 is phenyl, which may be optionally substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, or a group Q2; or corresponds to 2,2-difluoro-benzo[d][1,3]dioxol-4-yl; Q2 is a 5- or 6-membered heteroaryl containing at least one nitrogen atom, which may optionally substituted with n substituents selected from a group consisting of: Cl C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; P is a 6-membered heteroaryl or a 8-1 1 membered bicyclic heteroaryl group, which may be substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; R1 is hydrogen or C1-C3 alkyl; R2 is hydrogen or C1-C3 alkyl; n is 1, 2 or 3; p is 0, 1 or 2; and with the proviso that when R corresponds to phenyl, P is substituted by at least one CF3; processes for the preparation of those compounds, pharmaceutical compositions containing one or more compounds of formula (I) and their use as dual antagonists of the Orexin 1 and Orexin 2 receptors.

4,4-DIFLUORO-PIPERIDINE-COMPOUNDS

The invention, in a first aspect relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is a 6-membered aromatic ring, or a 5- or 6-membered heteroaromatic ring comprising 1 to 3 heteroatoms selected from S, O and N,